HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunscreen Bill Would Expedite TEA Decisions, Set Deadlines

This article was originally published in The Rose Sheet

Executive Summary

The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.

You may also be interested in...



House Sunscreen Bill Advances, But TEA Review Deadlines In Question

The House Energy and Commerce Health subcommittee unanimously advanced the Sunscreen Innovation Act to full committee June 19, but provisions in the original bill seeking a tight timeline for FDA’s review of sunscreen ingredient time-and-extent applications are now in limbo, according to the Public Access to Sunscreens coalition of stakeholders.

EWG Seeks Realistic FDA Review Deadlines In Sunscreen Innovation Act

While the Environmental Working Group supports the Sunscreen Innovation Act, it would like to see realistic deadlines put in place to accelerate FDA’s review of sunscreen-ingredient time-and-extent applications without including a default mechanism that would grant free market access to certain sunscreen actives when FDA fails to act within allotted timeframes.

Sunscreen Ingredient Legislation Could Ride Wave Of Momentum

Legislators and stakeholders are optimistic that the Sunscreen Innovation Act, which calls for an acceleration of FDA’s review of sunscreen active-ingredient time-and-extent applications, will pass this year. The House version of the bill is expected to advance first.

Related Content

UsernamePublicRestriction

Register

RS018958

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel